(Q24312148)

1

0 references

Sarah Lt Christensen

2

0 references

Sidse O Würtz

3

0 references

Martin Lundberg

4

0 references

Birgitte S Nielsen

5

0 references

Lena Vinther

6

0 references

Mick Knowles

7

0 references

Nick Gee

8

0 references

Simon Fredriksson

9

0 references

Susanne Møller

10

0 references

Nils Brünner

11

0 references

Anne-Sofie Schrohl

Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein

12

0 references

language of work or name

English

0 references

publication date

2013

0 references

published in

BMC Cancer

0 references

volume

13

0 references

issue

1

0 references

page(s)

598

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

19 March 2017

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

New functions for the matrix metalloproteinases in cancer progression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

Latent MMP-9 is bound to TIMP-1 before secretion

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

A biochemical model of matrix metalloproteinase 9 activation and inhibition

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

Rapid and individual-specific glycoprofiling of the low abundance N-glycosylated protein tissue inhibitor of metalloproteinases-1.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer

27 September 2017

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-598

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-598

Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-598

Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-598

Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-598

Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-598

Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-598

High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3878682

An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist

29 November 2018

1 reference

12 December 2020

Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis

1 reference

12 December 2020

Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients

1 reference

12 December 2020

High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer

1 reference

12 December 2020

Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1

1 reference

12 December 2020

Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories

1 reference

12 December 2020

High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study

1 reference

12 December 2020

Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study

1 reference

12 December 2020

A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-13-598

1 reference

Dimensions Publication ID

1035849760

0 references

1 reference

1 reference

PubMed publication ID

24330623

1 reference